These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions. Dang CT. Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859 [Abstract] [Full Text] [Related]
27. Docetaxel in breast cancer and a rationale for combination therapy. Hortobágyi G. Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):11-5. PubMed ID: 9213321 [Abstract] [Full Text] [Related]
28. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Lissoni P, Bucovec R, Malugani F, Ardizzoia A, Villa S, Gardani GS, Vaghi M, Tancini G. Anticancer Res; 2002 Jun; 22(2B):1131-4. PubMed ID: 12168912 [Abstract] [Full Text] [Related]
29. Paclitaxel and docetaxel in prostate cancer. Obasaju C, Hudes GR. Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295 [Abstract] [Full Text] [Related]
30. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies. Sparano JA. Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686 [Abstract] [Full Text] [Related]
31. Docetaxel in combination chemotherapy for metastatic breast cancer. Khayat D, Antoine E. Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513 [Abstract] [Full Text] [Related]
32. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. Gennari A, Guarneri V, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF. Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265 [Abstract] [Full Text] [Related]
33. Paclitaxel and docetaxel in breast and ovarian cancer. Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422 [Abstract] [Full Text] [Related]
34. Treatment of advanced breast cancer: current status. Piccart M. Anticancer Drugs; 1996 Aug; 7 Suppl 2():5-7. PubMed ID: 8862702 [Abstract] [Full Text] [Related]
35. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients. Ravdin PM. Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096 [Abstract] [Full Text] [Related]
36. [Progress and perspectives in palliative therapy of breast carcinoma]. Verlag GT. Dtsch Med Wochenschr; 1996 Dec 06; 121(49 Suppl):1-8. PubMed ID: 8983911 [No Abstract] [Full Text] [Related]
37. Paclitaxel and docetaxel in the treatment of breast cancer. Saloustros E, Mavroudis D, Georgoulias V. Expert Opin Pharmacother; 2008 Oct 06; 9(15):2603-16. PubMed ID: 18803448 [Abstract] [Full Text] [Related]
38. Docetaxel. Leahy M, Howell A. Br J Hosp Med; 2008 Oct 06; 57(4):141-4. PubMed ID: 9166374 [Abstract] [Full Text] [Related]
39. Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients. Ekholm E, Rantanen V, Bergman M, Vesalainen R, Antila K, Salminen E. Anticancer Res; 2000 Oct 06; 20(3B):2045-8. PubMed ID: 10928149 [Abstract] [Full Text] [Related]
40. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Clemons M, Leahy M, Valle J, Jayson G, Ranson M, Howell A. Eur J Cancer; 1997 Nov 06; 33(13):2183-93. PubMed ID: 9470804 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]